Verition Fund Management’s AstraZeneca AZN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-115,400
Closed -$13.4M 2716
2021
Q4
$13.4M Sell
115,400
-7,450
-6% -$877K 0.1% 127
2021
Q3
$14.8M Buy
122,850
+17,850
+17% +$2.08M 0.13% 112
2021
Q2
$12.6M Sell
105,000
-73,050
-41% -$8.01M 0.11% 108
2021
Q1
$17.7M Buy
178,050
+44,100
+33% +$4.43M 0.2% 71
2020
Q4
$13.4M Buy
+133,950
New +$14.2M 0.12% 111

Other funds holding AZN

Verition Fund Management's AZN Position: Q1 2026 in Review

Verition Fund Management sold out of AstraZeneca (AZN) in Q1 2026, closing a stake of 2,589 shares — an estimated $476K sold.

Verition Fund Management first reported a position in AZN in Q2 2013 and held it in 23 quarters. The position peaked at $160M in Q3 2021. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Verition Fund Management reported no remaining AstraZeneca position as of Q1 2026 after selling out during the quarter.
  • Verition Fund Management sold 2,589 AstraZeneca shares in Q1 2026, an estimated $476K.
  • Verition Fund Management first reported a position in AstraZeneca in Q2 2013 and held it in 23 quarters.
  • Verition Fund Management's AstraZeneca position peaked at $160M in Q3 2021.
  • 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.